10 Reasons Spreadsheet-Tracker CFOs on the Medication Are Switching to Onavya

Twelve years of column P holding flat. Nine months on the medication: negative ten pounds of lean mass. Think of your body as a house. The medication is taking off the paint and the drywall — the fat. The frame underneath is the lean mass. The frame was not supposed to come down. (The published lean-loss fraction for this drug class is around 39%, per the 2021 trial known as Wilding STEP 1.)

Protein and resistance training stress the contractile fibers and hand them the bricks they need. Necessary. But there's a layer underneath the bricks — the cellular furnaces inside every muscle cell. Those furnaces slow down when the body is in a sustained calorie deficit. Protein doesn't reach them. Lifting doesn't reach them. (Researchers call this layer the mitochondrial biogenesis axis — the cells' own factory line for new furnaces.)

You already tried the shelf. AG1 closed the nutrient gap. Creatine helped contractile output. Vital Proteins helped the skin question. None of them touched the cellular layer. You can stack four canisters on the counter and the lean-mass column still falls — because that column reads the layer underneath the layer those products work on.

Your PCP meant well. But "keep doing what you're doing" isn't a plan — it's a hope that the cellular layer will reset on its own. It doesn't. When the body is held in a sustained calorie deficit by the medication, the cellular furnace line slows whether you eat clean or not. Discipline doesn't reach that floor. A different molecule does.

Your muscle cells have walls. Most antioxidants protect only the outside. Astaxanthin sits inside the wall itself — including the wall around the cellular furnaces. Once it's there, it helps the furnaces hold their pace and protects the type-II fibers that lose strength first in any catabolic state. One molecule. Two jobs on the floor protein and lifting can't reach. (The science calls these PGC-1α support + type-II fiber oxidative protection.)

A 2018 randomized trial took adults 65 to 82 with measured muscle decline and split them in two groups. Both groups did light exercise. The group that added 12mg of this carotenoid for twelve weeks gained 14% strength, 40% endurance, and 8% mobility. The exercise-only group gained zero strength. (Liu 2018 on PubMed — full citation in the footnote below.)

The trial used 12 milligrams a day. Most astaxanthin softgels on the shelf sell 4 to 6mg — barely a third of what the researchers studied. Onavya delivers the full 12mg in a single softgel, sourced from a microalgae called Haematococcus pluvialis and paired with oil so your body actually absorbs it. No filler. No 4mg shortcut.

A 2020 review pooled twenty studies on this carotenoid and muscle health. The picture was consistent: reduced oxidative stress inside the muscle cell, slower breakdown of muscle protein, and more new cellular furnaces being built. (Wong, Ima-Nirwana, Chin 2020 on PubMed.) That's the layer protein and resistance training can't reach — described, measured, and mapped in twenty separate papers.

This isn't a drug and it isn't a powder. You take one small softgel with breakfast and walk away. No bloat. No fishy burps. No calf cramps. Across the human-trial literature, no serious side effects have been reported at doses up to 20mg a day. The most common note is a slightly reddish tint in stool — a harmless trait of the carotenoid family (the one that colors carrots and salmon).

Take it for twelve weeks — the same window the published trial tracked. Let your sports-medicine PCP read the next DEXA. If column P hasn't turned — if the lean-mass row hasn't moved the right way — full refund, no questions, no fine print. The risk lives on our side, not on the next row of your spreadsheet.